188 related articles for article (PubMed ID: 35975974)
1. The immune cell infiltrate in the tumour microenvironment of phaeochromocytomas and paragangliomas.
Tufton N; Hearnden RJ; Berney DM; Drake WM; Parvanta L; Chapple JP; Akker SA
Endocr Relat Cancer; 2022 Nov; 29(11):589-598. PubMed ID: 35975974
[TBL] [Abstract][Full Text] [Related]
2. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis.
van Nederveen FH; Gaal J; Favier J; Korpershoek E; Oldenburg RA; de Bruyn EM; Sleddens HF; Derkx P; Rivière J; Dannenberg H; Petri BJ; Komminoth P; Pacak K; Hop WC; Pollard PJ; Mannelli M; Bayley JP; Perren A; Niemann S; Verhofstad AA; de Bruïne AP; Maher ER; Tissier F; Méatchi T; Badoual C; Bertherat J; Amar L; Alataki D; Van Marck E; Ferrau F; François J; de Herder WW; Peeters MP; van Linge A; Lenders JW; Gimenez-Roqueplo AP; de Krijger RR; Dinjens WN
Lancet Oncol; 2009 Aug; 10(8):764-71. PubMed ID: 19576851
[TBL] [Abstract][Full Text] [Related]
3. Tumour microenvironment in pheochromocytoma and paraganglioma.
Martinelli S; Amore F; Canu L; Maggi M; Rapizzi E
Front Endocrinol (Lausanne); 2023; 14():1137456. PubMed ID: 37033265
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive characterisation of phaeochromocytoma and paraganglioma tumours through histone protein profiling, DNA methylation and transcriptomic analysis genome wide.
Chatzikyriakou P; Brempou D; Quinn M; Fishbein L; Noberini R; Anastopoulos IN; Tufton N; Lim ES; Obholzer R; Hubbard JG; Moonim M; Bonaldi T; Nathanson KL; Izatt L; Oakey RJ
Clin Epigenetics; 2023 Dec; 15(1):196. PubMed ID: 38124114
[TBL] [Abstract][Full Text] [Related]
5. Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas.
Wallace PW; Conrad C; Brückmann S; Pang Y; Caleiras E; Murakami M; Korpershoek E; Zhuang Z; Rapizzi E; Kroiss M; Gudziol V; Timmers HJ; Mannelli M; Pietzsch J; Beuschlein F; Pacak K; Robledo M; Klink B; Peitzsch M; Gill AJ; Tischler AS; de Krijger RR; Papathomas T; Aust D; Eisenhofer G; Richter S
J Pathol; 2020 Aug; 251(4):378-387. PubMed ID: 32462735
[TBL] [Abstract][Full Text] [Related]
6. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status.
Eisenhofer G; Lenders JW; Siegert G; Bornstein SR; Friberg P; Milosevic D; Mannelli M; Linehan WM; Adams K; Timmers HJ; Pacak K
Eur J Cancer; 2012 Jul; 48(11):1739-49. PubMed ID: 22036874
[TBL] [Abstract][Full Text] [Related]
7. ERBB-2 overexpression as a risk factor for malignant phaeochromocytomas and paraganglinomas.
Wang W; Zhong X; Ye L; Qi Y; Su T; Wei Q; Xie J; Jiang L; Jiang Y; Zhou W; Cui B; Ning G
Clin Endocrinol (Oxf); 2016 Jun; 84(6):822-9. PubMed ID: 26749044
[TBL] [Abstract][Full Text] [Related]
8. A comparative immunohistochemical study of phaeochromocytomas and paragangliomas.
Fraga M; García-Caballero T; Antúnez J; Couce M; Beiras A; Forteza J
Histol Histopathol; 1993 Jul; 8(3):429-36. PubMed ID: 8358154
[TBL] [Abstract][Full Text] [Related]
9. Establishment and evaluation of a novel biomarker-based nomogram for malignant phaeochromocytomas and paragangliomas.
Zhong X; Ye L; Su T; Xie J; Zhou W; Jiang Y; Jiang L; Ning G; Wang W
Clin Endocrinol (Oxf); 2017 Aug; 87(2):127-135. PubMed ID: 28429830
[TBL] [Abstract][Full Text] [Related]
10. Examination of PHOX2B in adult neuroendocrine neoplasms reveals relatively frequent expression in phaeochromocytomas and paragangliomas.
Lee JP; Hung YP; O'Dorisio TM; Howe JR; Hornick JL; Bellizzi AM
Histopathology; 2017 Oct; 71(4):503-510. PubMed ID: 28464318
[TBL] [Abstract][Full Text] [Related]
11. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma.
Kimura N; Takayanagi R; Takizawa N; Itagaki E; Katabami T; Kakoi N; Rakugi H; Ikeda Y; Tanabe A; Nigawara T; Ito S; Kimura I; Naruse M;
Endocr Relat Cancer; 2014 Jun; 21(3):405-14. PubMed ID: 24521857
[TBL] [Abstract][Full Text] [Related]
12. GIPC2 is an endocrine-specific tumor suppressor gene for both sporadic and hereditary tumors of RET- and SDHB-, but not VHL-associated clusters of pheochromocytoma/paraganglioma.
Dong Y; Huang Y; Fan C; Wang L; Zhang R; Li W; Guo Z; Wang D; Zheng Z
Cell Death Dis; 2021 May; 12(5):444. PubMed ID: 33947839
[TBL] [Abstract][Full Text] [Related]
13. Value of Immunohistochemical Expression of Apelin, Succinate Dehydrogenase B, Chromogranin B, Human Epidermal Growth Factor Receptor-2, Contactin 4, and Succinyl-CoA Synthetase Subunit Beta in Differentiating Metastatic From Non-Metastatic Pheochromocytoma and Paraganglioma.
Wang Y; Chen D; Pang Y; Xu X; Guan X; Liu L
Front Endocrinol (Lausanne); 2022; 13():882906. PubMed ID: 35574028
[TBL] [Abstract][Full Text] [Related]
14. SDHC phaeochromocytoma and paraganglioma: A UK-wide case series.
Williams ST; Chatzikyriakou P; Carroll PV; McGowan BM; Velusamy A; White G; Obholzer R; Akker S; Tufton N; Casey RT; Maher ER; Park SM; Porteous M; Dyer R; Tan T; Wernig F; Brady AF; Kosicka-Slawinska M; Whitelaw BC; Dorkins H; Lalloo F; Brennan P; Carlow J; Martin R; Mitchell AL; Harrison R; Hawkes L; Newell-Price J; Kelsall A; Igbokwe R; Adlard J; Schirwani S; Davidson R; Morrison PJ; Chung TT; Bowles C; Izatt L
Clin Endocrinol (Oxf); 2022 Apr; 96(4):499-512. PubMed ID: 34558728
[TBL] [Abstract][Full Text] [Related]
15. Long-term in vitro 2D-culture of SDHB and SDHD-related human paragangliomas and pheochromocytomas.
Bayley JP; Rebel HG; Scheurwater K; Duesman D; Zhang J; Schiavi F; Korpershoek E; Jansen JC; Schepers A; Devilee P
PLoS One; 2022; 17(9):e0274478. PubMed ID: 36178902
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations.
Bernardo-Castiñeira C; Valdés N; Celada L; Martinez ASJ; Sáenz-de-Santa-María I; Bayón GF; Fernández AF; Sierra MI; Fraga MF; Astudillo A; Jiménez-Fonseca P; Rial JC; Hevia MÁ; Turienzo E; Bernardo C; Forga L; Tena I; Molina-Garrido MJ; Cacho L; Villabona C; Serrano T; Scola B; Chirivella I; Del Olmo M; Menéndez CL; Navarro E; Tous M; Vallejo A; Athimulam S; Bancos I; Suarez C; Chiara MD
J Clin Endocrinol Metab; 2019 Nov; 104(11):5673-5692. PubMed ID: 31216007
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis of endocrine disease: Biochemical diagnosis of phaeochromocytoma and paraganglioma.
van Berkel A; Lenders JW; Timmers HJ
Eur J Endocrinol; 2014 Mar; 170(3):R109-19. PubMed ID: 24347425
[TBL] [Abstract][Full Text] [Related]
18. Activation of RAS Signalling is Associated with Altered Cell Adhesion in Phaeochromocytoma.
Rossitti HM; Dutta RK; Larsson C; Ghayee HK; Söderkvist P; Gimm O
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33138083
[TBL] [Abstract][Full Text] [Related]
19. Pseudohypoxia in paraganglioma and pheochromocytoma is associated with an immunosuppressive phenotype.
Celada L; Cubiella T; San-Juan-Guardado J; Gutiérrez G; Beiguela B; Rodriguez R; Poch M; Astudillo A; Grijalba A; Sánchez-Sobrino P; Tous M; Navarro E; Serrano T; Paja M; Valdés N; Chiara MD
J Pathol; 2023 Jan; 259(1):103-114. PubMed ID: 36314599
[TBL] [Abstract][Full Text] [Related]
20. Phaeochromocytomas and paragangliomas: A difference in disease behaviour and clinical outcomes.
Ezzat Abdel-Aziz T; Prete F; Conway G; Gaze M; Bomanji J; Bouloux P; Khoo B; Caplin M; Mushtaq I; Smart J; Kurzawinski TR
J Surg Oncol; 2015 Oct; 112(5):486-91. PubMed ID: 26337393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
